Global Amoxicillin

Amoxicillin Comprehensive Study by Application (Skin Infections, ENT (Ear, Nose & Throat) Infections, Stomach Infections, Lungs Infections, Urinary tract infections (UTI), Pneumonia, Bronchitis, Gonorrhea), Administration (Oral, Intravenous), Drug type (Tablets, Capsule, Suspensions, Syrup, Powder), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Players and Region - Global Market Outlook to 2025

Amoxicillin Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Amoxicillin Market?

Over the past few decades, the rise in the prevalence of respiratory infections, rising awareness regarding bacterial infections and antibiotics, and the presence of major players are likely to drive the Amoxicillin market. Amoxicillin is in a class of medications called penicillin-like antibiotics, it is used to treat infections caused by bacteria, such as bronchitis, pneumonia, and infections of the ears, nose, throat, urinary tract, and skin. It is also used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers. It works by stopping the growth of bacteria. Moreover, it also used to treat Amoxicillin also is sometimes used to treat Lyme disease, to prevent anthrax infection after exposure, and to treat anthrax infection of the skin. According to the World Health Organization Amoxicillin, and Amoxicillin in combination with Clavulanic Acid are the most frequently used antibiotics globally. Thus the demand for the Amoxicillin drug in the market

The market study is being classified, by Application (Skin Infections, ENT (Ear, Nose & Throat) Infections, Stomach Infections, Lungs Infections, Urinary tract infections (UTI), Pneumonia, Bronchitis and Gonorrhea) and major geographies with country level break-up.

United Laboratories (United States), GSK (United Kingdom), Novartis (Switzerland), Centrient Pharmaceuticals (Netherlands), Teva Pharmaceuticals (Israel), CSPC (China), Cipla (India), Hikma (United Kingdom), Dr. Redy (United States) and Sun Pharma (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Mylan (United States) and Aurubindo (India).

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States & United Kingdom Players will contribute to the maximum growth of Global Amoxicillin market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Amoxicillin market by Type, Application and Region.

On the basis of geography, the market of Amoxicillin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • The Rise in the prevalence of infectious diseases
  • Increasing awareness of various diseases and their treatment are the major factors contributing to the growth


Restraints
  • The adverse effect of the Amoxicillin drug can affect health

Opportunities
  • The rise in the cases of respiratory tract infection diseases across the world and the vulnerable aging population as this population is offers of the major opportunity for growth in the market

Challenges
  • The patent registration process of national regulation authorities





Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Amoxicillin Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Report Objectives / Segmentation Covered

By Application
  • Skin Infections
  • ENT (Ear, Nose & Throat) Infections
  • Stomach Infections
  • Lungs Infections
  • Urinary tract infections (UTI)
  • Pneumonia
  • Bronchitis
  • Gonorrhea
By Administration
  • Oral
  • Intravenous

By Drug type
  • Tablets
  • Capsule
  • Suspensions
  • Syrup
  • Powder

By End User
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rise in the prevalence of infectious diseases
      • 3.2.2. Increasing awareness of various diseases and their treatment are the major factors contributing to the growth
    • 3.3. Market Challenges
      • 3.3.1. The patent registration process of national regulation authorities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Amoxicillin, by Application, Administration, Drug type, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Amoxicillin (Value)
      • 5.2.1. Global Amoxicillin by: Application (Value)
        • 5.2.1.1. Skin Infections
        • 5.2.1.2. ENT (Ear, Nose & Throat) Infections
        • 5.2.1.3. Stomach Infections
        • 5.2.1.4. Lungs Infections
        • 5.2.1.5. Urinary tract infections (UTI)
        • 5.2.1.6. Pneumonia
        • 5.2.1.7. Bronchitis
        • 5.2.1.8. Gonorrhea
      • 5.2.2. Global Amoxicillin by: Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Intravenous
      • 5.2.3. Global Amoxicillin by: Drug type (Value)
        • 5.2.3.1. Tablets
        • 5.2.3.2. Capsule
        • 5.2.3.3. Suspensions
        • 5.2.3.4. Syrup
        • 5.2.3.5. Powder
      • 5.2.4. Global Amoxicillin by: End User (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Retail Pharmacy
        • 5.2.4.3. Online Pharmacy
      • 5.2.5. Global Amoxicillin Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Amoxicillin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. United Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GSK (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Centrient Pharmaceuticals (Netherlands)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceuticals (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CSPC (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cipla (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hikma (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Dr. Redy (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sun Pharma (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Amoxicillin Sale, by Application, Administration, Drug type, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Amoxicillin (Value)
      • 7.2.1. Global Amoxicillin by: Application (Value)
        • 7.2.1.1. Skin Infections
        • 7.2.1.2. ENT (Ear, Nose & Throat) Infections
        • 7.2.1.3. Stomach Infections
        • 7.2.1.4. Lungs Infections
        • 7.2.1.5. Urinary tract infections (UTI)
        • 7.2.1.6. Pneumonia
        • 7.2.1.7. Bronchitis
        • 7.2.1.8. Gonorrhea
      • 7.2.2. Global Amoxicillin by: Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Intravenous
      • 7.2.3. Global Amoxicillin by: Drug type (Value)
        • 7.2.3.1. Tablets
        • 7.2.3.2. Capsule
        • 7.2.3.3. Suspensions
        • 7.2.3.4. Syrup
        • 7.2.3.5. Powder
      • 7.2.4. Global Amoxicillin by: End User (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Retail Pharmacy
        • 7.2.4.3. Online Pharmacy
      • 7.2.5. Global Amoxicillin Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Amoxicillin: by Application(USD Million)
  • Table 2. Amoxicillin Skin Infections , by Region USD Million (2015-2020)
  • Table 3. Amoxicillin ENT (Ear, Nose & Throat) Infections , by Region USD Million (2015-2020)
  • Table 4. Amoxicillin Stomach Infections , by Region USD Million (2015-2020)
  • Table 5. Amoxicillin Lungs Infections , by Region USD Million (2015-2020)
  • Table 6. Amoxicillin Urinary tract infections (UTI) , by Region USD Million (2015-2020)
  • Table 7. Amoxicillin Pneumonia , by Region USD Million (2015-2020)
  • Table 8. Amoxicillin Bronchitis , by Region USD Million (2015-2020)
  • Table 9. Amoxicillin Gonorrhea , by Region USD Million (2015-2020)
  • Table 10. Amoxicillin: by Administration(USD Million)
  • Table 11. Amoxicillin Oral , by Region USD Million (2015-2020)
  • Table 12. Amoxicillin Intravenous , by Region USD Million (2015-2020)
  • Table 13. Amoxicillin: by Drug type(USD Million)
  • Table 14. Amoxicillin Tablets , by Region USD Million (2015-2020)
  • Table 15. Amoxicillin Capsule , by Region USD Million (2015-2020)
  • Table 16. Amoxicillin Suspensions , by Region USD Million (2015-2020)
  • Table 17. Amoxicillin Syrup , by Region USD Million (2015-2020)
  • Table 18. Amoxicillin Powder , by Region USD Million (2015-2020)
  • Table 19. Amoxicillin: by End User(USD Million)
  • Table 20. Amoxicillin Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 21. Amoxicillin Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 22. Amoxicillin Online Pharmacy , by Region USD Million (2015-2020)
  • Table 23. South America Amoxicillin, by Country USD Million (2015-2020)
  • Table 24. South America Amoxicillin, by Application USD Million (2015-2020)
  • Table 25. South America Amoxicillin, by Administration USD Million (2015-2020)
  • Table 26. South America Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 27. South America Amoxicillin, by End User USD Million (2015-2020)
  • Table 28. Brazil Amoxicillin, by Application USD Million (2015-2020)
  • Table 29. Brazil Amoxicillin, by Administration USD Million (2015-2020)
  • Table 30. Brazil Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 31. Brazil Amoxicillin, by End User USD Million (2015-2020)
  • Table 32. Argentina Amoxicillin, by Application USD Million (2015-2020)
  • Table 33. Argentina Amoxicillin, by Administration USD Million (2015-2020)
  • Table 34. Argentina Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 35. Argentina Amoxicillin, by End User USD Million (2015-2020)
  • Table 36. Rest of South America Amoxicillin, by Application USD Million (2015-2020)
  • Table 37. Rest of South America Amoxicillin, by Administration USD Million (2015-2020)
  • Table 38. Rest of South America Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 39. Rest of South America Amoxicillin, by End User USD Million (2015-2020)
  • Table 40. Asia Pacific Amoxicillin, by Country USD Million (2015-2020)
  • Table 41. Asia Pacific Amoxicillin, by Application USD Million (2015-2020)
  • Table 42. Asia Pacific Amoxicillin, by Administration USD Million (2015-2020)
  • Table 43. Asia Pacific Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 44. Asia Pacific Amoxicillin, by End User USD Million (2015-2020)
  • Table 45. China Amoxicillin, by Application USD Million (2015-2020)
  • Table 46. China Amoxicillin, by Administration USD Million (2015-2020)
  • Table 47. China Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 48. China Amoxicillin, by End User USD Million (2015-2020)
  • Table 49. Japan Amoxicillin, by Application USD Million (2015-2020)
  • Table 50. Japan Amoxicillin, by Administration USD Million (2015-2020)
  • Table 51. Japan Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 52. Japan Amoxicillin, by End User USD Million (2015-2020)
  • Table 53. India Amoxicillin, by Application USD Million (2015-2020)
  • Table 54. India Amoxicillin, by Administration USD Million (2015-2020)
  • Table 55. India Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 56. India Amoxicillin, by End User USD Million (2015-2020)
  • Table 57. South Korea Amoxicillin, by Application USD Million (2015-2020)
  • Table 58. South Korea Amoxicillin, by Administration USD Million (2015-2020)
  • Table 59. South Korea Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 60. South Korea Amoxicillin, by End User USD Million (2015-2020)
  • Table 61. Taiwan Amoxicillin, by Application USD Million (2015-2020)
  • Table 62. Taiwan Amoxicillin, by Administration USD Million (2015-2020)
  • Table 63. Taiwan Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 64. Taiwan Amoxicillin, by End User USD Million (2015-2020)
  • Table 65. Australia Amoxicillin, by Application USD Million (2015-2020)
  • Table 66. Australia Amoxicillin, by Administration USD Million (2015-2020)
  • Table 67. Australia Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 68. Australia Amoxicillin, by End User USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Amoxicillin, by Application USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Amoxicillin, by Administration USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Amoxicillin, by End User USD Million (2015-2020)
  • Table 73. Europe Amoxicillin, by Country USD Million (2015-2020)
  • Table 74. Europe Amoxicillin, by Application USD Million (2015-2020)
  • Table 75. Europe Amoxicillin, by Administration USD Million (2015-2020)
  • Table 76. Europe Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 77. Europe Amoxicillin, by End User USD Million (2015-2020)
  • Table 78. Germany Amoxicillin, by Application USD Million (2015-2020)
  • Table 79. Germany Amoxicillin, by Administration USD Million (2015-2020)
  • Table 80. Germany Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 81. Germany Amoxicillin, by End User USD Million (2015-2020)
  • Table 82. France Amoxicillin, by Application USD Million (2015-2020)
  • Table 83. France Amoxicillin, by Administration USD Million (2015-2020)
  • Table 84. France Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 85. France Amoxicillin, by End User USD Million (2015-2020)
  • Table 86. Italy Amoxicillin, by Application USD Million (2015-2020)
  • Table 87. Italy Amoxicillin, by Administration USD Million (2015-2020)
  • Table 88. Italy Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 89. Italy Amoxicillin, by End User USD Million (2015-2020)
  • Table 90. United Kingdom Amoxicillin, by Application USD Million (2015-2020)
  • Table 91. United Kingdom Amoxicillin, by Administration USD Million (2015-2020)
  • Table 92. United Kingdom Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 93. United Kingdom Amoxicillin, by End User USD Million (2015-2020)
  • Table 94. Netherlands Amoxicillin, by Application USD Million (2015-2020)
  • Table 95. Netherlands Amoxicillin, by Administration USD Million (2015-2020)
  • Table 96. Netherlands Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 97. Netherlands Amoxicillin, by End User USD Million (2015-2020)
  • Table 98. Rest of Europe Amoxicillin, by Application USD Million (2015-2020)
  • Table 99. Rest of Europe Amoxicillin, by Administration USD Million (2015-2020)
  • Table 100. Rest of Europe Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 101. Rest of Europe Amoxicillin, by End User USD Million (2015-2020)
  • Table 102. MEA Amoxicillin, by Country USD Million (2015-2020)
  • Table 103. MEA Amoxicillin, by Application USD Million (2015-2020)
  • Table 104. MEA Amoxicillin, by Administration USD Million (2015-2020)
  • Table 105. MEA Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 106. MEA Amoxicillin, by End User USD Million (2015-2020)
  • Table 107. Middle East Amoxicillin, by Application USD Million (2015-2020)
  • Table 108. Middle East Amoxicillin, by Administration USD Million (2015-2020)
  • Table 109. Middle East Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 110. Middle East Amoxicillin, by End User USD Million (2015-2020)
  • Table 111. Africa Amoxicillin, by Application USD Million (2015-2020)
  • Table 112. Africa Amoxicillin, by Administration USD Million (2015-2020)
  • Table 113. Africa Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 114. Africa Amoxicillin, by End User USD Million (2015-2020)
  • Table 115. North America Amoxicillin, by Country USD Million (2015-2020)
  • Table 116. North America Amoxicillin, by Application USD Million (2015-2020)
  • Table 117. North America Amoxicillin, by Administration USD Million (2015-2020)
  • Table 118. North America Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 119. North America Amoxicillin, by End User USD Million (2015-2020)
  • Table 120. United States Amoxicillin, by Application USD Million (2015-2020)
  • Table 121. United States Amoxicillin, by Administration USD Million (2015-2020)
  • Table 122. United States Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 123. United States Amoxicillin, by End User USD Million (2015-2020)
  • Table 124. Canada Amoxicillin, by Application USD Million (2015-2020)
  • Table 125. Canada Amoxicillin, by Administration USD Million (2015-2020)
  • Table 126. Canada Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 127. Canada Amoxicillin, by End User USD Million (2015-2020)
  • Table 128. Mexico Amoxicillin, by Application USD Million (2015-2020)
  • Table 129. Mexico Amoxicillin, by Administration USD Million (2015-2020)
  • Table 130. Mexico Amoxicillin, by Drug type USD Million (2015-2020)
  • Table 131. Mexico Amoxicillin, by End User USD Million (2015-2020)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Amoxicillin: by Application(USD Million)
  • Table 143. Amoxicillin Skin Infections , by Region USD Million (2021-2026)
  • Table 144. Amoxicillin ENT (Ear, Nose & Throat) Infections , by Region USD Million (2021-2026)
  • Table 145. Amoxicillin Stomach Infections , by Region USD Million (2021-2026)
  • Table 146. Amoxicillin Lungs Infections , by Region USD Million (2021-2026)
  • Table 147. Amoxicillin Urinary tract infections (UTI) , by Region USD Million (2021-2026)
  • Table 148. Amoxicillin Pneumonia , by Region USD Million (2021-2026)
  • Table 149. Amoxicillin Bronchitis , by Region USD Million (2021-2026)
  • Table 150. Amoxicillin Gonorrhea , by Region USD Million (2021-2026)
  • Table 151. Amoxicillin: by Administration(USD Million)
  • Table 152. Amoxicillin Oral , by Region USD Million (2021-2026)
  • Table 153. Amoxicillin Intravenous , by Region USD Million (2021-2026)
  • Table 154. Amoxicillin: by Drug type(USD Million)
  • Table 155. Amoxicillin Tablets , by Region USD Million (2021-2026)
  • Table 156. Amoxicillin Capsule , by Region USD Million (2021-2026)
  • Table 157. Amoxicillin Suspensions , by Region USD Million (2021-2026)
  • Table 158. Amoxicillin Syrup , by Region USD Million (2021-2026)
  • Table 159. Amoxicillin Powder , by Region USD Million (2021-2026)
  • Table 160. Amoxicillin: by End User(USD Million)
  • Table 161. Amoxicillin Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 162. Amoxicillin Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 163. Amoxicillin Online Pharmacy , by Region USD Million (2021-2026)
  • Table 164. South America Amoxicillin, by Country USD Million (2021-2026)
  • Table 165. South America Amoxicillin, by Application USD Million (2021-2026)
  • Table 166. South America Amoxicillin, by Administration USD Million (2021-2026)
  • Table 167. South America Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 168. South America Amoxicillin, by End User USD Million (2021-2026)
  • Table 169. Brazil Amoxicillin, by Application USD Million (2021-2026)
  • Table 170. Brazil Amoxicillin, by Administration USD Million (2021-2026)
  • Table 171. Brazil Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 172. Brazil Amoxicillin, by End User USD Million (2021-2026)
  • Table 173. Argentina Amoxicillin, by Application USD Million (2021-2026)
  • Table 174. Argentina Amoxicillin, by Administration USD Million (2021-2026)
  • Table 175. Argentina Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 176. Argentina Amoxicillin, by End User USD Million (2021-2026)
  • Table 177. Rest of South America Amoxicillin, by Application USD Million (2021-2026)
  • Table 178. Rest of South America Amoxicillin, by Administration USD Million (2021-2026)
  • Table 179. Rest of South America Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 180. Rest of South America Amoxicillin, by End User USD Million (2021-2026)
  • Table 181. Asia Pacific Amoxicillin, by Country USD Million (2021-2026)
  • Table 182. Asia Pacific Amoxicillin, by Application USD Million (2021-2026)
  • Table 183. Asia Pacific Amoxicillin, by Administration USD Million (2021-2026)
  • Table 184. Asia Pacific Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 185. Asia Pacific Amoxicillin, by End User USD Million (2021-2026)
  • Table 186. China Amoxicillin, by Application USD Million (2021-2026)
  • Table 187. China Amoxicillin, by Administration USD Million (2021-2026)
  • Table 188. China Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 189. China Amoxicillin, by End User USD Million (2021-2026)
  • Table 190. Japan Amoxicillin, by Application USD Million (2021-2026)
  • Table 191. Japan Amoxicillin, by Administration USD Million (2021-2026)
  • Table 192. Japan Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 193. Japan Amoxicillin, by End User USD Million (2021-2026)
  • Table 194. India Amoxicillin, by Application USD Million (2021-2026)
  • Table 195. India Amoxicillin, by Administration USD Million (2021-2026)
  • Table 196. India Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 197. India Amoxicillin, by End User USD Million (2021-2026)
  • Table 198. South Korea Amoxicillin, by Application USD Million (2021-2026)
  • Table 199. South Korea Amoxicillin, by Administration USD Million (2021-2026)
  • Table 200. South Korea Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 201. South Korea Amoxicillin, by End User USD Million (2021-2026)
  • Table 202. Taiwan Amoxicillin, by Application USD Million (2021-2026)
  • Table 203. Taiwan Amoxicillin, by Administration USD Million (2021-2026)
  • Table 204. Taiwan Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 205. Taiwan Amoxicillin, by End User USD Million (2021-2026)
  • Table 206. Australia Amoxicillin, by Application USD Million (2021-2026)
  • Table 207. Australia Amoxicillin, by Administration USD Million (2021-2026)
  • Table 208. Australia Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 209. Australia Amoxicillin, by End User USD Million (2021-2026)
  • Table 210. Rest of Asia-Pacific Amoxicillin, by Application USD Million (2021-2026)
  • Table 211. Rest of Asia-Pacific Amoxicillin, by Administration USD Million (2021-2026)
  • Table 212. Rest of Asia-Pacific Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific Amoxicillin, by End User USD Million (2021-2026)
  • Table 214. Europe Amoxicillin, by Country USD Million (2021-2026)
  • Table 215. Europe Amoxicillin, by Application USD Million (2021-2026)
  • Table 216. Europe Amoxicillin, by Administration USD Million (2021-2026)
  • Table 217. Europe Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 218. Europe Amoxicillin, by End User USD Million (2021-2026)
  • Table 219. Germany Amoxicillin, by Application USD Million (2021-2026)
  • Table 220. Germany Amoxicillin, by Administration USD Million (2021-2026)
  • Table 221. Germany Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 222. Germany Amoxicillin, by End User USD Million (2021-2026)
  • Table 223. France Amoxicillin, by Application USD Million (2021-2026)
  • Table 224. France Amoxicillin, by Administration USD Million (2021-2026)
  • Table 225. France Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 226. France Amoxicillin, by End User USD Million (2021-2026)
  • Table 227. Italy Amoxicillin, by Application USD Million (2021-2026)
  • Table 228. Italy Amoxicillin, by Administration USD Million (2021-2026)
  • Table 229. Italy Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 230. Italy Amoxicillin, by End User USD Million (2021-2026)
  • Table 231. United Kingdom Amoxicillin, by Application USD Million (2021-2026)
  • Table 232. United Kingdom Amoxicillin, by Administration USD Million (2021-2026)
  • Table 233. United Kingdom Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 234. United Kingdom Amoxicillin, by End User USD Million (2021-2026)
  • Table 235. Netherlands Amoxicillin, by Application USD Million (2021-2026)
  • Table 236. Netherlands Amoxicillin, by Administration USD Million (2021-2026)
  • Table 237. Netherlands Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 238. Netherlands Amoxicillin, by End User USD Million (2021-2026)
  • Table 239. Rest of Europe Amoxicillin, by Application USD Million (2021-2026)
  • Table 240. Rest of Europe Amoxicillin, by Administration USD Million (2021-2026)
  • Table 241. Rest of Europe Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 242. Rest of Europe Amoxicillin, by End User USD Million (2021-2026)
  • Table 243. MEA Amoxicillin, by Country USD Million (2021-2026)
  • Table 244. MEA Amoxicillin, by Application USD Million (2021-2026)
  • Table 245. MEA Amoxicillin, by Administration USD Million (2021-2026)
  • Table 246. MEA Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 247. MEA Amoxicillin, by End User USD Million (2021-2026)
  • Table 248. Middle East Amoxicillin, by Application USD Million (2021-2026)
  • Table 249. Middle East Amoxicillin, by Administration USD Million (2021-2026)
  • Table 250. Middle East Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 251. Middle East Amoxicillin, by End User USD Million (2021-2026)
  • Table 252. Africa Amoxicillin, by Application USD Million (2021-2026)
  • Table 253. Africa Amoxicillin, by Administration USD Million (2021-2026)
  • Table 254. Africa Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 255. Africa Amoxicillin, by End User USD Million (2021-2026)
  • Table 256. North America Amoxicillin, by Country USD Million (2021-2026)
  • Table 257. North America Amoxicillin, by Application USD Million (2021-2026)
  • Table 258. North America Amoxicillin, by Administration USD Million (2021-2026)
  • Table 259. North America Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 260. North America Amoxicillin, by End User USD Million (2021-2026)
  • Table 261. United States Amoxicillin, by Application USD Million (2021-2026)
  • Table 262. United States Amoxicillin, by Administration USD Million (2021-2026)
  • Table 263. United States Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 264. United States Amoxicillin, by End User USD Million (2021-2026)
  • Table 265. Canada Amoxicillin, by Application USD Million (2021-2026)
  • Table 266. Canada Amoxicillin, by Administration USD Million (2021-2026)
  • Table 267. Canada Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 268. Canada Amoxicillin, by End User USD Million (2021-2026)
  • Table 269. Mexico Amoxicillin, by Application USD Million (2021-2026)
  • Table 270. Mexico Amoxicillin, by Administration USD Million (2021-2026)
  • Table 271. Mexico Amoxicillin, by Drug type USD Million (2021-2026)
  • Table 272. Mexico Amoxicillin, by End User USD Million (2021-2026)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Amoxicillin: by Application USD Million (2015-2020)
  • Figure 5. Global Amoxicillin: by Administration USD Million (2015-2020)
  • Figure 6. Global Amoxicillin: by Drug type USD Million (2015-2020)
  • Figure 7. Global Amoxicillin: by End User USD Million (2015-2020)
  • Figure 8. South America Amoxicillin Share (%), by Country
  • Figure 9. Asia Pacific Amoxicillin Share (%), by Country
  • Figure 10. Europe Amoxicillin Share (%), by Country
  • Figure 11. MEA Amoxicillin Share (%), by Country
  • Figure 12. North America Amoxicillin Share (%), by Country
  • Figure 13. Global Amoxicillin share by Players 2020 (%)
  • Figure 14. Global Amoxicillin share by Players (Top 3) 2020(%)
  • Figure 15. Global Amoxicillin share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. United Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. United Laboratories (United States) Revenue: by Geography 2020
  • Figure 19. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 21. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 23. Centrient Pharmaceuticals (Netherlands) Revenue, Net Income and Gross profit
  • Figure 24. Centrient Pharmaceuticals (Netherlands) Revenue: by Geography 2020
  • Figure 25. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 26. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 27. CSPC (China) Revenue, Net Income and Gross profit
  • Figure 28. CSPC (China) Revenue: by Geography 2020
  • Figure 29. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 30. Cipla (India) Revenue: by Geography 2020
  • Figure 31. Hikma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. Hikma (United Kingdom) Revenue: by Geography 2020
  • Figure 33. Dr. Redy (United States) Revenue, Net Income and Gross profit
  • Figure 34. Dr. Redy (United States) Revenue: by Geography 2020
  • Figure 35. Sun Pharma (India) Revenue, Net Income and Gross profit
  • Figure 36. Sun Pharma (India) Revenue: by Geography 2020
  • Figure 37. Global Amoxicillin: by Application USD Million (2021-2026)
  • Figure 38. Global Amoxicillin: by Administration USD Million (2021-2026)
  • Figure 39. Global Amoxicillin: by Drug type USD Million (2021-2026)
  • Figure 40. Global Amoxicillin: by End User USD Million (2021-2026)
  • Figure 41. South America Amoxicillin Share (%), by Country
  • Figure 42. Asia Pacific Amoxicillin Share (%), by Country
  • Figure 43. Europe Amoxicillin Share (%), by Country
  • Figure 44. MEA Amoxicillin Share (%), by Country
  • Figure 45. North America Amoxicillin Share (%), by Country
List of companies from research coverage that are profiled in the study
  • United Laboratories (United States)
  • GSK (United Kingdom)
  • Novartis (Switzerland)
  • Centrient Pharmaceuticals (Netherlands)
  • Teva Pharmaceuticals (Israel)
  • CSPC (China)
  • Cipla (India)
  • Hikma (United Kingdom)
  • Dr. Redy (United States)
  • Sun Pharma (India)
Additional players considered in the study are as follows:
Mylan (United States) , Aurubindo (India)
Select User Access Type

Key Highlights of Report


Dec 2020 202 Pages 89 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Amoxicillin Quantitative research analysis
Global Amoxicillin Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"The Rise in the prevalence of infectious diseases " is seen as one of major growth factors of Amoxicillin Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Amoxicillin Report?

Have a Query? Click Here

Other Related Reports

Lutein Supplements Comprehensive Study by Nature (Organic, Synthetic), Form (Powder, Tablets, Oil Suspension, Emulsion, Others), Distribution Channel (Online Stores, Medical Stores, Nutraceutical Sto...
$ 3650
Multiple Sclerosis Drugs Comprehensive Study by Type (Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Primary-Progressive MS (PPMS), Secondary-Progressive MS (SPMS)), Route of Admi...
$ 3450
Dog Care Comprehensive Study by Type (Dog Food, Treats & Chews, Toys & Training, Apparel & Accessories, Grooming & Healthcare, Shelter & Accessories, Other), Application (Young Dogs, Old Dogs), Distr...
$ 3450
Human DNA Vaccines Comprehensive Study by Type (Human DNA vaccines, Animal DNA vaccines), Application (Human diseases {(Oncology-Pancreatic cancer, Breast cancer, Ovarian cancer, Small cell lung canc...
$ 3750
Thioctic Acid Comprehensive Study by Type (R-lipoic Acid, S-lipoic Acid), Application (Diabetes, Nerve Pain, Weight Loss, Skin Care, Others), Distribution Channel (Online (E-Commerce Stores), Offline...
$ 3650
Histidine Comprehensive Study by Type (Tablets, Capsules, Fluids, Others), Application (Food Industry, Pharmaceutical Industry, Biotechnology, R&D Laboratories, Medical Research Institutes, Others), ...
$ 3450